Download PDF
Exp Clin Endocrinol Diabetes 1989; 94(6): 357-362
DOI: 10.1055/s-0029-1210922
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Persistence of Anti-Islet ADCC after Manifestation of Type-1 (Insulin-Dependent) Diabetes

Erika Köhler, S. Knospe, W. Besch, D. Michaelis, Ilona Rjasanowski
  • Central Institute of Diabetes “Gerhardt Katsch”, Karlsburg, GDR
Further Information

Publication History

1988

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

ADCC (antibody-dependent cellular cytotoxicity) against xenogenic islets in vitro has frequently been found with mononuclear blood cells and heat inactivated autologous serum from newly diagnosed Type-1 diabetics. Anti-islet ADCC, as measured by enhanced 51Cr-release of islets after a 6h-incubation, leads to functional alteration of islets such as a decrease in insulin content and in leucine incorporation. In a follow-up investigation over at least three years it was demonstrated that anti-islet ADCC in vitro disappears, if there is no more C-peptide secretion in vivo. Furthermore, anti-islet ADCC has also not been found in long-term Type-1 diabetics who had no C-peptide secretion but an acutely stimulated immune system due to infectious diseases. An acute immunocytolytic process against pancreatic beta cells in vivo seems to be the precondition for anti-islet ADCC in vitro.

Key Words

Type-1 diabetes - Anti-islet ADCC - C-peptide - Infectious diseases

      >